- Patent Title: PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
-
Application No.: US15487548Application Date: 2017-04-14
-
Publication No.: US10167472B2Publication Date: 2019-01-01
- Inventor: Lyndi Rice , Michelle Pusey , Ewa Wandzioch , Sophie Marie Genevieve Bail , Amy Lynn Wenda
- Applicant: Medical Diagnostic Laboratories, L.L.C.
- Applicant Address: US NJ Hamilton
- Assignee: Medical Diagnostic Laboratories, LLC
- Current Assignee: Medical Diagnostic Laboratories, LLC
- Current Assignee Address: US NJ Hamilton
- Agent Terence J. Bogle; Jessica Downing
- Main IPC: A61K31/70
- IPC: A61K31/70 ; C07H21/02 ; C07H21/04 ; C12N15/113 ; C12Q1/6886 ; G01N33/574 ; A61K31/713 ; A61K31/7105 ; C12N5/00
Abstract:
Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
Public/Granted literature
Information query
